Eclipsebio

Eclipsebio operates as a specialized service and platform provider in the rapidly growing RNA therapeutics space. Its core value proposition is an integrated, end-to-end offering that combines AI-powered sequence design (eNAVIGATE), rapid in-house RNA prototyping, and a proprietary suite of sequencing-first analytical assays (eMERGE platform) to de-risk and accelerate client programs. The company has expanded its capabilities through the acquisition of Terrain Bio and serves partners across modalities including RNAi, ASOs, mRNA, and small molecules, providing critical data on structure, modifications, and off-target effects. While not developing its own therapeutics, Eclipsebio's technology and data services are foundational for companies advancing RNA drugs toward the clinic.

Integrated 'eMERGE' platform combining AI-powered sequence design (eNAVIGATE), rapid RNA prototyping, and a suite of proprietary sequencing-based assays (eSHAPE, eSENSE, eCLIP variants, Nanopore) for multi-dimensional RNA characterization and analytics.

Eclipsebio competes in the RNA services and CRO space against large, diversified players like LabCorp and Charles River, as well as other specialized genomics service providers. Its differentiation lies in its integrated, proprietary platform focused exclusively on RNA and its ability to provide multi-omic, sequencing-first insights for therapeutic development.